Covid Usa, green light for FDA emergency use of Modern booster in over 18s

Green light from the US Food and Drug Administration (Fda) for the emergency use of Moderna’s anti-Covid vaccine booster in the US for people aged 18 and over. The booster of this vaccine provides a dose of 50 micrograms, equal to half that used for the primary vaccination course. The American company announced the extension of the emergency use authorization granted by the FDA for the booster. The booster – explains Moderna in a note – can be used in all over 18s who have completed a primary vaccination with any other authorized or approved Covid-19 vaccine. This authorization “comes at a critical moment, as we enter the winter months and face an increase in Covid cases and hospitalizations across the country – says Stéphane Bancel, CEO of Moderna – We thank the FDA for its review and we are confident in solid clinical evidence that a booster dose of 50 µg of mRna-1273 “, the Spikevax vaccine *,” induces a strong immune response against Covid “. The booster dose should be administered, reads Moderna’s note, “at least 6 months after completion of any primary vaccination.” As a next step, the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) will meet to discuss a potential recommendation for the roll-out of anti-Covid boosters among Americans.